| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2023 | 2.56% | Goldman Sachs | $1.4 → $1.6 | Maintains | Buy |
| 09/27/2023 | 28.21% | Canaccord Genuity | → $2 | Reiterates | Hold → Hold |
| 08/15/2023 | 28.21% | Canaccord Genuity | → $2 | Reiterates | Hold → Hold |
| 08/10/2023 | -3.85% | Wells Fargo | $1 → $1.5 | Maintains | Equal-Weight |
| 05/15/2023 | -16.67% | Keefe, Bruyette & Woods | $1.4 → $1.3 | Maintains | Market Perform |
| 05/15/2023 | 28.21% | Canaccord Genuity | → $2 | Reiterates | Hold → Hold |
| 05/11/2023 | -16.67% | Goldman Sachs | $1.5 → $1.3 | Maintains | Buy |
| 05/10/2023 | -35.9% | Piper Sandler | $1.3 → $1 | Maintains | Neutral |
| 05/10/2023 | -35.9% | Wells Fargo | $1.5 → $1 | Maintains | Equal-Weight |
| 05/10/2023 | -16.67% | Goldman Sachs | $1.5 → $1.3 | Maintains | Buy |
| 04/28/2023 | -3.85% | Goldman Sachs | $2.5 → $1.5 | Maintains | Buy |
| 03/20/2023 | -16.67% | Piper Sandler | $2.4 → $1.3 | Maintains | Neutral |
| 03/17/2023 | -3.85% | Wells Fargo | $2 → $1.5 | Maintains | Equal-Weight |
| 03/17/2023 | 28.21% | Canaccord Genuity | $3 → $2 | Maintains | Hold |
| 03/09/2023 | -10.26% | Keefe, Bruyette & Woods | $1.3 → $1.4 | Maintains | Market Perform |
| 01/11/2023 | 28.21% | Wells Fargo | $2.5 → $2 | Maintains | Equal-Weight |
| 11/14/2022 | 92.31% | Canaccord Genuity | $4 → $3 | Maintains | Hold |
| 11/14/2022 | 44.23% | Keefe, Bruyette & Woods | → $2.25 | Upgrades | Underperform → Market Perform |
| 11/11/2022 | 60.26% | Wells Fargo | $3 → $2.5 | Maintains | Equal-Weight |
| 11/11/2022 | 53.85% | Piper Sandler | $3.2 → $2.4 | Maintains | Neutral |
| 10/18/2022 | 108.33% | Goldman Sachs | $5.25 → $3.25 | Maintains | Buy |
| 08/19/2022 | 156.41% | Canaccord Genuity | $5 → $4 | Maintains | Hold |
| 08/16/2022 | 105.13% | Piper Sandler | $2.5 → $3.2 | Maintains | Neutral |
| 07/25/2022 | 76.28% | Keefe, Bruyette & Woods | $4 → $2.75 | Downgrades | Market Perform → Underperform |
| 07/18/2022 | 60.26% | Piper Sandler | $3.5 → $2.5 | Maintains | Neutral |
| 07/07/2022 | 220.51% | Keybanc | → $5 | Downgrades | Overweight → Sector Weight |
| 05/25/2022 | 169.23% | Compass Point | → $4.2 | Initiates Coverage On | → Neutral |
| 05/13/2022 | 124.36% | Piper Sandler | $5.5 → $3.5 | Maintains | Neutral |
| 05/13/2022 | 92.31% | Wells Fargo | $5 → $3 | Maintains | Equal-Weight |
| 04/19/2022 | 348.72% | Goldman Sachs | $8 → $7 | Maintains | Buy |
| 04/04/2022 | 412.82% | Goldman Sachs | $9 → $8 | Maintains | Buy |
| 04/04/2022 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 04/01/2022 | 252.56% | Truist Securities | $7.5 → $5.5 | Maintains | Hold |
| 04/01/2022 | 220.51% | Canaccord Genuity | $28 → $5 | Downgrades | Buy → Hold |
| 04/01/2022 | 220.51% | Wells Fargo | → $5 | Downgrades | Overweight → Equal-Weight |
| 04/01/2022 | 252.56% | Piper Sandler | $10 → $5.5 | Downgrades | Overweight → Neutral |
| 04/01/2022 | 284.62% | Keybanc | $10 → $6 | Maintains | Overweight |
| 03/31/2022 | 476.92% | Goldman Sachs | $23 → $9 | Maintains | Buy |
| 03/21/2022 | 380.77% | Truist Securities | → $7.5 | Downgrades | Buy → Hold |
| 03/15/2022 | 605.13% | Wells Fargo | $15 → $11 | Maintains | Overweight |
| 02/14/2022 | 653.21% | Keefe, Bruyette & Woods | → $11.75 | Initiates Coverage On | → Market Perform |
| 01/25/2022 | 541.03% | Keybanc | $16 → $10 | Maintains | Overweight |
| 01/13/2022 | 541.03% | Piper Sandler | $13 → $10 | Maintains | Overweight |
| 12/13/2021 | 861.54% | Wells Fargo | $20 → $15 | Maintains | Overweight |
| 12/10/2021 | 733.33% | Piper Sandler | $19 → $13 | Maintains | Overweight |
| 11/12/2021 | 925.64% | Keybanc | $22 → $16 | Maintains | Overweight |
| 11/11/2021 | 1117.95% | Piper Sandler | $24 → $19 | Maintains | Overweight |
| 08/20/2021 | 1310.26% | Keybanc | $25 → $22 | Maintains | Overweight |
| 08/10/2021 | 1182.05% | UBS | → $20 | Initiates Coverage On | → Neutral |
| 08/10/2021 | 1438.46% | Wells Fargo | → $24 | Initiates Coverage On | → Overweight |
| 08/10/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 08/10/2021 | 1694.87% | Canaccord Genuity | → $28 | Initiates Coverage On | → Buy |
| 08/10/2021 | 1438.46% | Truist Securities | → $24 | Initiates Coverage On | → Buy |
| 08/10/2021 | 1823.08% | Goldman Sachs | → $30 | Initiates Coverage On | → Buy |
| 08/10/2021 | 1502.56% | Keybanc | → $25 | Initiates Coverage On | → Overweight |
| 08/10/2021 | 1438.46% | Piper Sandler | → $24 | Initiates Coverage On | → Overweight |
What is the target price for Blend Labs (BLND)?
The latest price target for Blend Labs (NYSE: BLND) was reported by Goldman Sachs on November 8, 2023. The analyst firm set a price target for $1.60 expecting BLND to rise to within 12 months (a possible 2.56% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Blend Labs (BLND)?
The latest analyst rating for Blend Labs (NYSE: BLND) was provided by Goldman Sachs, and Blend Labs maintained their buy rating.
When is the next analyst rating going to be posted or updated for Blend Labs (BLND)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Blend Labs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Blend Labs was filed on November 8, 2023 so you should expect the next rating to be made available sometime around November 8, 2024.
Is the Analyst Rating Blend Labs (BLND) correct?
While ratings are subjective and will change, the latest Blend Labs (BLND) rating was a maintained with a price target of $1.40 to $1.60. The current price Blend Labs (BLND) is trading at is $1.56, which is within the analyst's predicted range.